Mutant p53 as an Antigen in Cancer Immunotherapy.

Int J Mol Sci · 2020 · PMC7312027 · PMID 32521648

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Although their data failed to reach statistical significance, they postulated an interesting hypothesis that s-p53Abs could be used to monitor CRC disease progression [ 109 ].

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.